The least you can do is check in on them regularly
Approved Uses: Ozempic is primarily prescribed for managing type 2 diabetes but also has weight loss benefits
In December 2025, Eli Lilly published the first positive Phase 3 readout for retatrutide (LY3437943), the triple-agonist peptide that had, until then, only been validated at Phase 2 scale
Efficacy and Safety of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, in People with Type 2 Diabetes and Inadequate Glycaemic Control with Diet and Exercise (TRANSCEND-T2D-1): A Double-Blind, Randomised, Phase 3 Trial
The reduced risk was consistent when studying only patients with Type 2 diabetes (RR 0.54) or patients without diabetes (RR 0.52)
Pancreatic safety of incretin-based drugsFDA and EMA assessment